MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Price, Forecast & Analysis
USA - NYSEARCA:MTNB - US5768103039 - Common Stock
MTNB Key Statistics, Chart & Performance
The current stock price of MTNB is 1.18 USD. In the past month the price decreased by -28.48%. In the past year, price increased by 91.59%.
MTNB Latest News, Press Relases and Analysis
MTNB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.75 | 413.15B | ||
| AMGN | AMGEN INC | 15.73 | 185.19B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.09 | 111.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 76.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 906.47 | 60.60B | ||
| INSM | INSMED INC | N/A | 42.62B | ||
| NTRA | NATERA INC | N/A | 29.32B | ||
| BIIB | BIOGEN INC | 10.09 | 24.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 21.56B | ||
| INCY | INCYTE CORP | 16.18 | 20.29B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.17 | 13.75B |
Related stock screener links
About MTNB
Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Company Info
MATINAS BIOPHARMA HOLDINGS I
Suite 302, 1545 Route 206 South
Bedminster NEW JERSEY 07921 US
CEO: Jerome D. Jabbour
Employees: 3
Phone: 19084431860
MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ
Can you describe the business of MATINAS BIOPHARMA HOLDINGS I?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
What is the current price of MTNB stock?
The current stock price of MTNB is 1.18 USD.
What is the dividend status of MATINAS BIOPHARMA HOLDINGS I?
MTNB does not pay a dividend.
What is the ChartMill rating of MATINAS BIOPHARMA HOLDINGS I stock?
MTNB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of MATINAS BIOPHARMA HOLDINGS I (MTNB) based on its PE ratio?
MATINAS BIOPHARMA HOLDINGS I (MTNB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.17).
Would investing in MATINAS BIOPHARMA HOLDINGS I be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MTNB.
What is the next earnings date for MTNB stock?
MATINAS BIOPHARMA HOLDINGS I (MTNB) will report earnings on 2026-04-13, after the market close.
MTNB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MTNB. When comparing the yearly performance of all stocks, MTNB is one of the better performing stocks in the market, outperforming 88.03% of all stocks.
MTNB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MTNB. MTNB has a bad profitability rating. Also its financial health evaluation is rather negative.
MTNB Financial Highlights
Over the last trailing twelve months MTNB reported a non-GAAP Earnings per Share(EPS) of -4.17. The EPS increased by 24.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -212.28% | ||
| ROE | -315.97% | ||
| Debt/Equity | 0 |